Pre-made Tinurilimab benchmark antibody ( Whole mAb, anti-CEACAM6/CD66c therapeutic antibody, Anti-CEAL/NCA Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-578

Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tinurilimab (formerly BAY 1834942) is a humanised monoclonal antibody that selectively blocks the immune checkpoint regulator CEACAM6.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-578-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody
INN Name Tinurilimab
TargetCD66c
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesBayer;German Cancer Research Center
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna